Related references
Note: Only part of the references are listed.Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies
Ronit Gurion et al.
HAEMATOLOGICA (2022)
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities
QuanQiu Wang et al.
BLOOD REVIEWS (2021)
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
Francesco Passamonti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
Lee M. Greenberger et al.
CANCER CELL (2021)
Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies
Daniel Re et al.
LEUKEMIA & LYMPHOMA (2021)
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study
Isabel Regalado-Artamendi et al.
HEMASPHERE (2021)
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The first two cases of 2019-nCoV in Italy: Where they come from?
Marta Giovanetti et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Wenhua Liang et al.
LANCET ONCOLOGY (2020)
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
Safiya Richardson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak
Mengyuan Dai et al.
CANCER DISCOVERY (2020)
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta et al.
CANCER DISCOVERY (2020)
Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Annemarie B. Docherty et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
Sonu Bhaskar et al.
FRONTIERS IN IMMUNOLOGY (2020)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2020)
Determinants of COVID-19 disease severity in patients with cancer
Elizabeth V. Robilotti et al.
NATURE MEDICINE (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira et al.
BLOOD (2020)
Age-specific mortality and immunity patterns of SARS-CoV-2
Megan O'Driscoll et al.
NATURE (2020)
A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma
Joanna L. Moore et al.
AMERICAN JOURNAL OF CASE REPORTS (2020)
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
Sylvain Lamure et al.
ECLINICALMEDICINE (2020)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Share Paper
